Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis

Table 5 Prediction of hepatocellular carcinoma development by APRI-r1 in combination with suboptimal treatment response

Criteria	Univariate analysis					Multivariate analysis1
	HR		95%CI	P value	P trend	HR	95%CI	P value	P trend
Rotterdam
Low-risk	Ref	-		-		Ref	-	-
Intermediate-risk	2.81	0.56-14.01		0.208	< 0.0012	1.54	0.25-9.63	0.644	0.0062
High-risk	10.29	2.55-41.48		0.0012		7.95	1.56-40.45	0.0122
Paris I
Low-risk	Ref	-		-		Ref	-	-
Intermediate-risk	2.81	0.63-12.60		0.177	0.0032	2.34	0.40-13.60	0.345	0.0132
High-risk	8.38	1.99-35.21		0.004		7.28	1.45-36.71	0.0162
Barcelona
Low-risk	Ref	-		-		Ref	-	-
Intermediate-risk	1.28	0.29-5.72		0.75	0.0022	0.53	0.08-3.34	0.496	0.0382
High-risk	10.66	2.85-39.89		< 0.0012		5.54	1.29-23.71	0.0212
Toronto
Low-risk	Ref	-		-		Ref	-	-
Intermediate-risk	3.25	0.81-13.06		0.097	0.052	4.4	0.97-19.90	0.055	0.061
High-risk	4.22	0.85-20.97		0.079		4.77	0.78-29.24	0.091

¹The adjusted HR for suboptimal response was derived by multivariate analysis with other significant variables in Table 3 (age, male sex, cirrhosis and albumin) included;

²P-values < 0.05. Separate multivariate analysis was performed for each criteria in defining suboptimal response. In the multivariate analyses, albumin was not included for the Rotterdam criteria, as this variable was already included in the criteria. APRI-r1: AST/platelet ratio index at 1-year; CI: Confidence interval; HR: Hazard ratio.